Daily pill to help keep weight off after stopping obesity jabs

• Orforglipron is a daily oral tablet offering an alternative to GLP-1 receptor agonist injections for weight maintenance after obesity treatment cessation
• The medication is already available in the US with UK launch anticipated, potentially expanding treatment options for patients who prefer or cannot tolerate injectable therapies
• This development addresses the clinical challenge of weight regain following discontinuation of obesity medications, though efficacy data compared to established agents should be carefully reviewed

The tablet - orforglipron - is available in the US and could soon launch in the UK.

ClinicaliQ summarises and contextualises external updates for clinical awareness, then links to the original publisher for the full article and most current context.